Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer

Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024


Innovative study design allows for potential accelerated approval in untreated and previously...

Related Keywords

Santiago ,Regióetropolitana ,Chile ,United Kingdom ,Cambridge ,Cambridgeshire ,Kevin Lee ,Drug Administration ,Exchange Commission ,Bicycle Therapeutics ,Santiago Arroyo ,Webcast Information ,Bicycle Toxin Conjugate ,Cancer Research United Kingdom Centre ,Private Securities Litigation Reform Act ,Quarterly Report ,Markets ,